Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
research agreements Strong technical expertise in one or more of the following areas: Drug delivery systems (nanoparticles, liposomes, polymeric formulations) Biopharmaceutics and pharmacokinetics Biomarker
-
nanoparticles contribute to diseases. Environmental Nanoparticles of interest include those emitted from wildfires, traffic and micro-nanoplastics, the byproduct of degradation of plastics in environmental media
-
biopesticide: A sustainable approach to crop protection”. More specifically, they will contribute to the production and physical-chemical characterisation of lipid nanoparticles containing RNA and evaluate
-
Offer Description R2-A RESEARCHER. - REQUIRED DEGREE: PhD in Biomedicine/Microbiology. - PROJECT: "Formulation of Bacteriophages as Liposomes and Nanoparticles with potential application to the treatment
-
undertake a PhD in the NanoPhotonics Group (NP) led by Prof Jeremy J Baumberg, FRS (https://www.np.phy.cam.ac.uk/ ), as part of a prestigious European collaboration on building DNA origami for nanomachinery
-
and animal models. Develop and optimize siRNA formulations and encapsulation strategies in lipid- or nanoparticle-based delivery systems. Perform in vivo testing of siRNA-loaded nanoliposomes in disease
-
personalized therapy based on bioinspired nonlamellar LYotropic colloid Nanoparticles with Tumor homing ability (GLYNT)” with reference 2023.13674.PEX, supported by national funds by FCT / MECI, is available
-
MRC DiMeN Doctoral Training Partnership: Targeting Iron-Laden Macrophages with Therapeutic Nanoparticles to Improve Recovery After Haemorrhagic Stroke MRC DiMeN Doctoral Training Partnership PhD
-
. The main objective will be to functionalize the surface of these 3D metal parts, obtained by additive manufacturing, with a coating based on metal oxide nanoparticles. This coating must have a dual
-
organoid platforms (hIPSC), lipid nanoparticle (LNP)-mRNA with scaling and QC, and antisense oligonucleotide to perturb human m(i)RNA targets. Benchmarking platforms in rodent models and human organoids